Research Summary
SS-31 is a mitochondria-targeting tetrapeptide investigated for its role in improving mitochondrial function and reducing oxidative stress in cellular and animal models.
Evidence profile
Human Phase 3 evidence
10 cited publications · 2 primary trials · 1 derived analysis
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Thompson WR et al. · Genetics in medicine : official journal of the American College of Medical Genetics · 2024
The study reportedElamipretide was associated with sustained long-term tolerability and efficacy, with improvements in functional assessments and cardiac function in BTHS.
Karaa A et al. · Neurology · 2023
The study reportedSubcutaneous elamipretide treatment did not improve outcomes in the 6MWT and PMMSA TFS in patients with PMM. However, this phase-3 study demonstrated that subcutaneous elamipretide is well-tolerated.
Karaa A et al. · Orphanet journal of rare diseases · 2024 · PMID 39574155
Xie M et al. · Lung · 2026 · PMID 41801306
Zheng H et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025 · PMID 39848110
Patai R et al. · GeroScience · 2025 · PMID 40169521
Hao Y et al. · Cell communication and signaling : CCS · 2024 · PMID 38200543
Silvaroli JA et al. · Journal of the American Society of Nephrology : JASN · 2024 · PMID 38530359
Zhang H et al. · Journal of neuroinflammation · 2023 · PMID 36609266
Nie Y et al. · Antioxidants (Basel, Switzerland) · 2023 · PMID 38136142
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.
SS-31 has been investigated in clinical research settings but is not broadly approved as a therapeutic product.